By now, most of published papers about IRF-7 focused on IRF-7A, the major splicing variant.
Interferon (IFN) regulatory factor 7 (IRF-7) has several splicing variants, and at least the major splicing variant (IRF-7A) has oncogenic potential and is associated with EBV transformation processes.
Heterologous expression of the three major splice variants of the rat PAC1 receptor, PAC1hop, null and hip, in neural NG108-15 conferredferred PACAP-mediated intracellular cAMP generation, while elevation of [Ca2+]i occurred only in PAC1hop-, and to a lesser extent in PAC1null-expressing cells.
There are three major splice variants called QKI-5, QKI-6 and QKI-7 that encode different protein isoforms.
As reported in that study, there are two major splice variants for the coding sequence of zebra finch FoxP2.
In most CEACAM1-expressing cell types, the molecule occurs in two major splice variants differing in their cytoplasmic domain, called CEACAM1-L and CEACAM1-S.
Furthermore, CEACAM1 occurs in four major splice variants with either three or four Ig domains and either a short (S) or a long (L) cytoplasmic domain consisting of 12 aa or 73 aa residues, respectively, giving the following variants: CEACAM1-3S, CEACAM1-3L, CEACAM1-4L[15] CEACAM1-4L[15], [17].
The major splice variants are VEGF121, VEGF165, VEGF189 and VEGF206.
GRα and GRβ are the two major splice variants of GR as a result of alternative splicing.
